导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.11% | 349/593 |
| 近一周 | -1.60% | 238/634 |
| 近一月 | -3.51% | 272/631 |
| 近一季 | -7.29% | 347/613 |
| 近半年 | -3.69% | 291/597 |
| 近一年 | -0.27% | 298/565 |
| 近两年 | 42.24% | 253/458 |
| 近三年 | 22.88% | 192/362 |
| 成立以来 | 81.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.75% 3396/4961 |
12.38% 2187/5312 |
- - |
- - |
| 2025 | 18.93% 2271/4813 |
-1.08% 2572/3635 |
1.55% 2286/4076 |
18.54% 2286/4524 |
-0.12% 2368/4813 |
| 2024 | 13.07% 1185/3463 |
2.20% 806/2808 |
-1.56% 1075/3014 |
15.12% 1806/3129 |
-2.38% 2064/3463 |
| 2023 | -10.74% 1328/2656 |
3.84% 1112/2280 |
-5.05% 1356/2385 |
-3.46% 936/2515 |
-6.22% 1675/2655 |
| 2022 | -19.15% 806/2207 |
-14.53% 962/1919 |
6.97% 562/2016 |
-12.65% 751/2113 |
1.23% 1336/2208 |
| 2021 | 8.98% 464/1822 |
-2.57% 668/1255 |
10.67% 443/1330 |
-1.36% 521/1466 |
2.46% 587/1822 |
| 2020 | 42.98% 255/1250 |
-7.20% 529/1028 |
16.51% 432/1067 |
15.25% 227/1164 |
14.75% 251/1184 |
| 2019 | 39.54% 280/1092 |
27.55% 342/754 |
-1.37% 308/804 |
1.97% 337/850 |
8.77% 292/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.63% 328/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 平安MSCI中国A股国际ETF VS. 长安沪深300非周期A(740101) |